BRISTOL MYERS SQUIBB

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

Asunaprevir/Daclatasvir Safety Surveillance in Japanese Patients With Chronic Hepatitis C

Completed

Conditions: Chronic Hepatitis C

First Posted Date: 2014-09-26

Last Posted Date: 2017-05-03

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 2974

Registration Number: NCT02250001

Locations: 🇯🇵
Local Institution, Chuo-ku, Tokyo, Japan

BMS-986012 in Relapsed/Refractory SCLC

Phase 1

Completed

Conditions: Small Cell Lung Cancer

Interventions: Biological: BMS-986012 (anti-fucosyl-GM1)
Biological: Nivolumab

First Posted Date: 2014-09-25

Last Posted Date: 2024-03-05

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 106

Registration Number: NCT02247349

Locations: 🇧🇪
Local Institution - 0015, Gent, Belgium
🇧🇪
Local Institution - 0012, Liege, Belgium
🇵🇷
Local Institution - 0009, San Juan, Puerto Rico

and more 13 locations

Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)

Phase 3

Completed

Conditions: Advanced Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma

Interventions: Biological: Nivolumab
Biological: Ipilimumab
Drug: Sunitinib

First Posted Date: 2014-09-04

Last Posted Date: 2025-05-25

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1390

Registration Number: NCT02231749

Locations: 🇪🇸
Local Institution - 0089, Barcelona, Spain
🇪🇸
Local Institution - 0088, Barcelona, Spain
🇪🇸
Local Institution - 0086, Madrid, Spain

and more 186 locations

Phase 1b/2, Open Label, Repeat Dose, Dose Escalation Study of ND-L02-s0201 Injection in Subjects With Moderate to Extensive Fibrosis (METAVIR F3-4)

Phase 1

Completed

Conditions: Moderate to Extensive Hepatic Fibrosis (METAVIR F3-4)

Interventions: Drug: ND-L02-s0201 Injection

First Posted Date: 2014-08-28

Last Posted Date: 2017-05-11

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 25

Registration Number: NCT02227459

Locations: 🇺🇸
Texas Liver Institute, Austin, Texas, United States
🇧🇬
Tokuda Hospital, Sofia, Bulgaria

A Phase 1 Drug-drug Interaction Study in Healthy Volunteers

Phase 1

Completed

Conditions: Drug-drug Interaction Study

Interventions: Drug: BMS-986020
Drug: Montelukast
Drug: Flurbiprofen
Drug: Digoxin

First Posted Date: 2014-08-27

Last Posted Date: 2014-11-18

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 20

Registration Number: NCT02227173

Locations: 🇺🇸
Healthcare Discoveries, LLC d/b/a ICON Development Solutions, San Antonio, Texas, United States

YERVOY® Risk Minimization Tool Effectiveness Evaluation Survey

Completed

Conditions: Advanced Melanoma

Interventions: Drug: Ipilimumab

First Posted Date: 2014-08-25

Last Posted Date: 2015-12-21

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 158

Registration Number: NCT02224768

Locations: 🇬🇧
Local Institution, St. Ives, Cambridgeshire, United Kingdom
🇺🇸
Bristol-Myers Squibb, Princeton, New Jersey, United States

Suicidality and Suicide Attempt Among HIV Patients on Efavirenz-containing Versus Efavirenz-free Antiretroviral Regimens

Completed

Conditions: HIV Infection

First Posted Date: 2014-08-08

Last Posted Date: 2014-10-15

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 11400

Registration Number: NCT02211807

A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986104 in Healthy Male Subjects

Phase 1

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: BMS-986104
Drug: Placebo

First Posted Date: 2014-08-07

Last Posted Date: 2015-09-18

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 41

Registration Number: NCT02211469

Locations: 🇺🇸
Covance Clinical Research Unit, Inc., Madison, Wisconsin, United States

Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-986120 in Healthy Subjects and the Effects of Co-Administration of Midazolam and BMS-986120

Phase 1

Completed

Conditions: Healthy Adult Volunteers

Interventions: Drug: BMS-986120
Drug: Placebo
Drug: Midazolam

First Posted Date: 2014-08-05

Last Posted Date: 2015-07-07

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 24

Registration Number: NCT02208882

Locations: 🇺🇸
Ppd Development, Lp, Austin, Texas, United States

Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic Melanoma

Conditions: Malignant Melanoma

First Posted Date: 2014-07-10

Last Posted Date: 2017-02-08

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT02186249

Locations: 🇺🇸
Medstar Health Research Institute, Baltimore, Maryland, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

and more 61 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy